Peapod Lane Capital LLC purchased a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 227,239 shares of the biotechnology company’s stock, valued at approximately $550,000.
A number of other hedge funds have also recently made changes to their positions in the company. BML Capital Management LLC raised its holdings in Oramed Pharmaceuticals by 62.1% in the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after buying an additional 837,153 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Oramed Pharmaceuticals in the 3rd quarter valued at approximately $272,000. Marquette Asset Management LLC bought a new position in shares of Oramed Pharmaceuticals during the fourth quarter valued at $81,000. Dimensional Fund Advisors LP lifted its holdings in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares during the period. Finally, XTX Topco Ltd grew its stake in shares of Oramed Pharmaceuticals by 59.7% in the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares during the last quarter. 12.73% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, StockNews.com lowered Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 6th.
Oramed Pharmaceuticals Price Performance
Shares of Oramed Pharmaceuticals stock opened at $2.47 on Thursday. The stock’s 50-day moving average is $2.35 and its 200 day moving average is $2.37. Oramed Pharmaceuticals Inc. has a one year low of $2.00 and a one year high of $3.67. The firm has a market cap of $99.57 million, a price-to-earnings ratio of 22.45 and a beta of 1.66.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Further Reading
- Five stocks we like better than Oramed Pharmaceuticals
- 3 Fintech Stocks With Good 2021 Prospects
- Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
- What Are Dividend Champions? How to Invest in the Champions
- Double-Digit Gains Ahead? These 2 Cybersecurity Stocks Look Ready
- Dividend Capture Strategy: What You Need to Know
- Will Falling Bond Yields Send These 2 Small Caps Soaring?
Want to see what other hedge funds are holding ORMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report).
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
